- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06423326
Gemcitabina, cisplatina e Nab-Paclitaxel como tratamento neoadjuvante para pacientes com câncer de pâncreas ressecável ou limítrofe ressecável
Um ensaio clínico de fase II de braço único de gemcitabina, cisplatina e Nab-Paclitaxel como terapia neoadjuvante para adenocarcinoma ductal pancreático
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy is more feasible and could improve outcomes compared to patients receiving surgery first. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel, an antimicrotubule agent that stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel may have fewer side effects and work better than other forms of paclitaxel. Gemcitabine, cisplatin and nab-paclitaxel may be an effective neoadjuvant treatment option for patients with resectable or borderline resectable pancreatic cancer.
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVE:
I. Determine the clinical response rate of biweekly gemcitabine, cisplatin and nab-paclitaxel (GCN) in the neoadjuvant setting for patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
SECONDARY OBJECTIVE:
I. Determine if neoadjuvant GCN increases tumoral infiltration of lymphocytes with local and systemic phenotypic features that assist in the antitumor immune response.
OUTLINE:
Patients receive nab-paclitaxel intravenously (IV) over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 15 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease, partial or complete response undergo surgical resection per standard of care. Additionally, patients undergo biopsy on study and undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) at pre-study and on study.
After completion of study treatment, patients are followed up every 3-4 months for up to 24 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Mihir M. Shah, MD, MS, FACS, FSSO
- Número de telefone: 202-877-4599
- E-mail: Mihir.M.Shah@MedStar.net
Locais de estudo
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Ainda não está recrutando
- Lombardi Comprehensive Cancer Center, Georgetown University
-
Contato:
- Susan Lawrence, RN
- Número de telefone: 202-784-2725
- E-mail: sl2328@georgetown.edu
-
Investigador principal:
- MIhir M. Shah, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Hospital/Winship Cancer Institute
-
Contato:
- Kathleen M. Coleman
- E-mail: kathleen.marie.coleman@emory.edu
-
Investigador principal:
- Hussein Hamad, MD, MPH
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically or cytologically confirmed - resectable and borderline resectable pancreatic ductal adenocarcinoma
- Resectability will be defined as per National Comprehensive Cancer Network (NCCN) guidelines using cross-sectional imaging (contrast-enhanced computed tomography or magnetic resonance imaging scans of the abdomen, and pelvis)
- Decisions about resectability status will be made in consensus at multidisciplinary meetings/discussions
Resectable disease will be defined as:
- No interface of the tumor with celiac artery, common hepatic artery (CHA), or superior mesenteric arteries (SMA) (and, if present, variants)
- Less than 180° interface between tumor and vessel wall of the portal or superior mesenteric veins (SMV) without vein contour irregularity
- For tumors of the body and tail of the pancreas, interface with the splenic artery and splenic vein of any degree will be considered resectable disease
Borderline resectable disease will be defined as:
-
To include at least one of the following:
- Tumor abutment < 180° of the superior mesenteric artery or celiac axis
- Solid tumor contact with CHA without extension to celiac artery (CA) or hepatic artery bifurcation allowing for safe and complete resection and reconstruction
- Solid tumor contact with variant arterial anatomy (ex: accessory right hepatic artery, replaced right hepatic artery, replaced CHA, and the origin of replaced or accessory artery)
- Tumor induced narrowing of SMV, portal vein (PV) or SMV-PV of > 180˚ of the diameter of the vessel
- Short segment occlusion of the SMV, PV or SMV-PV with a suitable PV above and SMV below, for reconstruction
- Solid tumor contact with inferior vena cava
- Biopsy proven N1 disease (regional lymph nodes involved) from pre-referral biopsy or endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA)
-
No distant extrapancreatic disease (M0)
-
Adults > 18 years of age
-
Able to give informed consent
-
Able to adhere to study visit schedule and other protocol requirements
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
-
Adequate Bone marrow reserves as evidenced by:
- Absolute neutrophil count (ANC) ≥ 1,500 cells/ul
- Platelet count ≥ 100,000 cells/ul
- Hemoglobin ≥ 9 g/dL
-
Adequate hepatic function as evidence by:
- Serum total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
- Albumin ≥ 3 g/dl
-
Adequate renal function as evidenced by Creatinine ≤ 1.5 x ULN
-
Male, or a non-pregnant and non-lactating female
-
Women of child-bearing potential - defined as a sexually mature woman who has not undergone hysterectomy - the surgical removal of the uterus or bilateral oophorectomy - the surgical removal of both ovaries or has not been naturally postmenopausal for at least 24 consecutive months, i.e., has had menses at any time during the preceding 24 consecutive months, must commit to true abstinence from heterosexual contact, or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting gemcitabine/cisplatin/nab- paclitaxel (including dose interruptions) until treatment with gemcitabine/cisplatin/nab-paclitaxel is complete
-
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with gemcitabine/cisplatin/nab-paclitaxel and for 6 months following gemcitabine/cisplatin/nab- paclitaxel discontinuation, even if he has undergone a successful vasectomy
Exclusion Criteria:
- Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is defined as "moderate symptoms; limiting instrumental activities of daily living (ADLs)"
- Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, uncontrolled diabetes, serious active, uncontrolled infection after inadequate biliary drainage if tumor obstructing bile duct, or psychiatric illness/social situations
- Pregnancy (positive pregnancy test) or lactation
- Known central nervous system (CNS) disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (radiosurgery [RS]; Gamma Knife, linear accelerator [LINAC], or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded
- Previous (within the past 5 years) or concurrent presence of other untreated cancer, except nonmelanoma skin cancer and in situ carcinomas
- History of allergy or hypersensitivity to any of the study drugs
- Current abuse of alcohol or illicit drugs
- Inability or unwillingness to sign the informed consent form
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treatment (nab-paclitaxel, cisplatin, gemcitabine)
Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 15 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease, partial or complete response undergo surgical resection per standard of care. Additionally, patients undergo biopsy on study and undergo blood sample collection and CT or MRI at pre-study and on study. |
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Given IV
Outros nomes:
Undergo biopsy
Outros nomes:
Given IV
Outros nomes:
Undergo surgical resection
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical Response Rate to Neoadjuvant Chemotherapy
Prazo: Up to 24 months
|
Clinical response is defined as biochemical, radiological, pathological response or stable disease. • Biochemical response (or CA 19-9 response) is defined as >50% decrease from baseline with tumor response. Radiologic response is defined as complete response (CR), partial response (PR) or stable disease (SD) after the neoadjuvant therapy per RECIST 1.1. Pathologic response is defined by CAP scoring system as 0 (complete response), 1 (moderate response), 2 (minimal response) and 3 (poor or no response). Stable disease is defined as the absence of biochemical response (>50% CA 19-9 reduction), radiological response (per RECIST 1.1), or major pathological response (CAP Score 0-1), without metastasis / unresectability, and patient undergoes surgical resection. Clinical response rate (including clinical, biochemical, radiological, pathological response or stable disease) will be reported as a proportion, with an exact 90% confidence interval estimated using the Clopper-Pearson method. |
Up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment Completion
Prazo: Up to 24 months
|
Feasibility will be defined as completion of all preoperative and operative therapy. Treatment completion will reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. |
Up to 24 months
|
|
Incidence of Adverse Events (AEs)
Prazo: Up to 28 days after last dose of study treatment
|
AEs, with severity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics will be reported, using frequencies and percentages for each toxicity. |
Up to 28 days after last dose of study treatment
|
|
Radiologic Response Rate
Prazo: Up to 24 months
|
Radiological response rate will be defined as complete response, partial response or stable disease after study treatment evaluated using Response Evaluation Criteria in Solid Tumors version 1.1. Radiologic response rate will be reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. |
Up to 24 months
|
|
Pathological Response Rate
Prazo: Up to 24 months
|
To assess the major pathological response rate (CAP 0-1) in the surgical resection specimen |
Up to 24 months
|
|
Neoadjuvant Systemic Chemotherapy Rate
Prazo: Up to 4 months
|
To assess the rate of neoadjuvant systemic chemotherapy completion (Duration 4 months) without dose reduction |
Up to 4 months
|
|
R0 Resection Rate
Prazo: At time of surgery
|
R0 resection indicates a microscopically margin-negative resection. R0 resection rate will reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. |
At time of surgery
|
|
Nodal Status
Prazo: Up to 24 months
|
N0, N1, and N2 will be reported using frequencies and percentages. |
Up to 24 months
|
|
Recurrence-Free Survival (RFS)
Prazo: From surgery to recurrence or death, assessed up to 24 months
|
RFS will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median RFS will be estimated using the Brookmeyer-Crowley approach. |
From surgery to recurrence or death, assessed up to 24 months
|
|
Overall Survival (OS) Rate
Prazo: From study treatment start to date of death, assessed up to 24 months
|
OS will be estimated using the Kaplan-Meier method, and median survival will be calculated. A 95% confidence interval will be estimated using the Brookmeyer-Crowley approach. |
From study treatment start to date of death, assessed up to 24 months
|
|
Carbohydrate Antigen (CA)19-9 response
Prazo: Up to 24 months
|
CA19-9 response will be defined as > 50% decrease from baseline will be correlated with tumor response. CA19-9 will be reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. CA19-9 will be correlated with RFS and OS using log-rank tests and Cox proportional hazards regression. Model assumptions will be checked and verified. |
Up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Mihir M. Shah, MD, MS, FACS, FSSO, Georgetown University Lombardi Comprehensive Cancer Center, Medstar Health
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Neoplasias por local
- Neoplasias
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Neoplasias das Glândulas Endócrinas
- Doenças pancreáticas
- Neoplasias Pancreáticas
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Citodiagnóstico
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Taxóides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Elementos
- Metais
- Economia de saúde e organizações
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Metais, pesados
- Compostos de platina
- Elementos de transição
- Álbumins
- Paclitaxel
- Economia
- Paclitaxel ligado à albumina
- Gemcitabina
- Cisplatina
- Citrato de 1,2-diaminociclohexanoplatina II
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Platina
- Paclitaxel com 130 nm de albumina
- Impostos
Outros números de identificação do estudo
- STUDY00010624
- STUDY00006976 (Outro identificador: Emory University Hospital/Winship Cancer Institute)
- WINSHIP6093-23 (Outro identificador: Emory University Hospital/Winship Cancer Institute)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .